Nkarta, Inc. Derivative, Gain (Loss) on Derivative, Net
Nkarta, Inc. (NKTX) reported Derivative, Gain (Loss) on Derivative, Net of $858.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-25.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeGainLossOnDerivativeNet · last filed 2021-03-25
- Nkarta, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2019-12-31 was $0.00.
- Nkarta, Inc. derivative, gain (loss) on derivative, net for fiscal 2019 was $858.00K.
| Period end | Derivative, Gain (Loss) on Derivative, Net 3 month | Derivative, Gain (Loss) on Derivative, Net 9 month | Derivative, Gain (Loss) on Derivative, Net 12 month |
|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $858.00K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $858.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |